Regulatory Requirements for Early Clinical Testing of Novel HCV Antiviral Drugs: FDA Perspective, Jeff Murray, M.D., M.P.H. FDA, Division of Antiviral Products
Reported by Jules Levin
5th International Workshop on Clinical Pharmacology of Hepatitis Therapy
June 23-24, 2010
Boston, MA
